At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SPRC SciSparc Ltd.
Trading 12-22 10:48:30 EST
1.44
-0.02
-1.37%
High1.45Low1.41Vol39.11K
Open1.41D1 Closing1.46Amplitude2.74%
Mkt Cap4.72MTradable Cap4.72MTotal Shares3.28M
T/O56.21KT/O Rate1.19%Tradable Shares3.28M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Scisparc Ltd - Neurothera to Buy 55% Equity Interest in Target Company
THOMSON REUTERS  ·  12-02
Scisparc Ltd - Neurothera to Buy 55% Equity Interest in Target Company
Scisparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
THOMSON REUTERS  ·  12-02
Scisparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
Neurothera Labs to Acquire 55% Stake in Quantum Bio Data Company
Reuters  ·  12-02
Neurothera Labs to Acquire 55% Stake in Quantum Bio Data Company
BRIEF-Scisparc Plans On Entering The Multi-Billion-Dollar Gerd Device Market With Acquisition Of An Approved IP Portfolio
Reuters  ·  12-01
BRIEF-Scisparc Plans On Entering The Multi-Billion-Dollar Gerd Device Market With Acquisition Of An Approved IP Portfolio
SciSparc Acquires MUSE System IP Portfolio from Xylo Technologies
Reuters  ·  12-01
SciSparc Acquires MUSE System IP Portfolio from Xylo Technologies
Scisparc Ltd - to Issue 19.99% Share Capital to Xylo
THOMSON REUTERS  ·  12-01
Scisparc Ltd - to Issue 19.99% Share Capital to Xylo
Scisparc Plans on Entering the Multi-Billion-Dollar Gerd Device Market With Acquisition of an Approved Ip Portfolio
THOMSON REUTERS  ·  12-01
Scisparc Plans on Entering the Multi-Billion-Dollar Gerd Device Market With Acquisition of an Approved Ip Portfolio
Scisparc Ltd: Entered Into Securities Purchase Agreement ,to Issue Aggregate of 1.29Mln Ordinary Shares at$1.75-SEC Filing
THOMSON REUTERS  ·  11-28
Scisparc Ltd: Entered Into Securities Purchase Agreement ,to Issue Aggregate of 1.29Mln Ordinary Shares at$1.75-SEC Filing
BUZZ-U.S. STOCKS ON THE MOVE-Nucor, Natgas companies, health insurers
Reuters  ·  11-27
BUZZ-U.S. STOCKS ON THE MOVE-Nucor, Natgas companies, health insurers
BUZZ-U.S. STOCKS ON THE MOVE-Robinhood Markets, Oracle, Grindr
Reuters  ·  11-26
BUZZ-U.S. STOCKS ON THE MOVE-Robinhood Markets, Oracle, Grindr
Why SciSparc Stock Is Gaining Today
Benzinga  ·  11-26
Why SciSparc Stock Is Gaining Today
Scisparc Shares Climb 26%; Co to Buy Patents, Intellectual Property Rights for Medical Devices From Xylo
THOMSON REUTERS  ·  11-26
Scisparc Shares Climb 26%; Co to Buy Patents, Intellectual Property Rights for Medical Devices From Xylo
BUZZ-U.S. STOCKS ON THE MOVE-CleanSpark, Salesforce, Tesla
Reuters  ·  11-26
BUZZ-U.S. STOCKS ON THE MOVE-CleanSpark, Salesforce, Tesla
BUZZ-SciSparc jumps after deal to buy Xylo's medical device patents
Reuters  ·  11-26
BUZZ-SciSparc jumps after deal to buy Xylo's medical device patents
SciSparc to acquire treasury of patents for medical endoscopy systems
TIPRANKS  ·  11-26
SciSparc to acquire treasury of patents for medical endoscopy systems
Scisparc Shares Climb 27.5% Premarket; Co Says Will Buy a Treasury of Patents, Trademarks and Intellectual Property Rights From Xylo
THOMSON REUTERS  ·  11-26
Scisparc Shares Climb 27.5% Premarket; Co Says Will Buy a Treasury of Patents, Trademarks and Intellectual Property Rights From Xylo
BRIEF-Scisparc To Acquire Treasury Of Patents For Innovative Medical Endoscopy Systems
Reuters  ·  11-26
BRIEF-Scisparc To Acquire Treasury Of Patents For Innovative Medical Endoscopy Systems
SciSparc to Acquire Xylo’s MUSE Endoscopy IP Portfolio
Reuters  ·  11-26
SciSparc to Acquire Xylo’s MUSE Endoscopy IP Portfolio
Scisparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
THOMSON REUTERS  ·  11-26
Scisparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
Scisparc Ltd - Upon Deal Close, to Issue Shares Representing 19.99% to Xylo
THOMSON REUTERS  ·  11-26
Scisparc Ltd - Upon Deal Close, to Issue Shares Representing 19.99% to Xylo

Introduction

Company Name.
SciSparc Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Issue price:
--